• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva initiates U.S. recall of Topotecan metastatic ovarian cancer injection treatment

July 1, 2021 By Sean Whooley

TevaTeva Pharmaceuticals (NYSE:TEVA) initiated a voluntary recall of a lot of its Topotecan injection 4mg/4mL (1mg/mL) in the U.S.

The voluntary recall came as a result of a complaint received from a pharmacy after a single glass particle was observed inside one vial. Following further examination of the complaint sample, two other particulates were found and identified as one grey silicone particle and one translucent, colorless cotton fiber.

According to an FDA notice, the administration of an injectable product that contains particulate matter could result in local irritation or swelling as a response to the foreign material. Should the particulate reach the blood vessels, it could travel to various organs and block blood vessels in the heart, lungs or brain, potentially causing stroke and possibly leading to death.

Teva’s internal assessment determined that, while the health hazard could prove severe, the likelihood of patient exposure to the impacted product is remote or unlikely. The company has received no further complaints or reports of illness or injury.

Topotecan as a single agent is indicated for treating patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy and for patients with small-cell lung cancer platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy.

The treatment is also indicated for treating patients with Stage IV-B, recurrent or persistent cervical cancer that is not amenable to curative treatment, in combination with cisplatin. Teva distributed the product nationwide to six of its wholesale customers.

Customers were notified by the company on June 18 and were asked to recall the affected lot and make arrangements for returning impacted products.

Affected Product:

Carton NDC Vial NDC Lot# Exp. Date
0703-4714-01 0703-4714-71 31328962B 04/2022

 

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Immunotherapy, Oncology, Recalls Tagged With: FDA, Teva, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS